PCN48 Cost-Benefit Analysis of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

Saved in:
Bibliographic Details
Published in:Value in health 2021-06, Vol.24, p.S27-S27
Main Authors: Deniz, B., Onyekwere, U., Moran, D., Chioda, M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2021.04.140